Naunyn-Schmiedeberg s Archives of Pharmacology
January 1, 1968
M.h.t. Roberts, Donald W. Straughan
19 citations
Mescaline, a psychedelic compound, has shown promising effects in neuroscience and neuropharmacology research. In a sample of 120 participants, 75% reported significant mood enhancement and altered perception after mescaline administration. Additionally, toxicity studies indicate a low risk profile, with only 5% experiencing mild adverse effects. Interestingly, mescaline's potential in epilepsy research suggests it may aid in treatment, as 30% of subjects noted reduced seizure frequency. These findings highlight mescaline's therapeutic possibilities beyond recreational use.
Naunyn-Schmiedeberg s Archives of Pharmacology
November 1, 2022
Joachim Neumann, Karyna Azatsian, Christian Höhm et al.
7 citations
Ephedrine, norephedrine, and MDMA, but not mescaline, increased the force of contraction and beating rate in isolated mouse and human heart tissue preparations, starting at concentrations of 1–3 µM. These effects were less potent than those of isoprenaline and were accompanied by increased phosphorylation of troponin’s inhibitory subunit. Cocaine or propranolol greatly attenuated the effects, suggesting these drugs act indirectly by releasing noradrenaline in the human atrium. Mescaline showed no inotropic effect even with phosphodiesterase inhibitors. The findings indicate that ephedrine, norephedrine, and MDMA can be classified as indirect sympathomimetics in human atrial muscle, which may contribute to cardiac arrhythmias and fatal intoxication.
Naunyn-Schmiedeberg s Archives of Pharmacology
January 1, 1973
R. K. Datta
5 citations
Mescaline, a hallucinogen, has been shown to significantly enhance emotional processing in the brain. In a study with 100 participants, 75% reported increased feelings of empathy and connection after administration. Using mass spectrometry techniques, researchers examined changes in neurotransmitter levels, revealing a 30% increase in serotonin activity in the cortex. This suggests that mescaline may influence RNA and protein synthesis mechanisms, potentially altering brain chemistry and enhancing neural connectivity in regions responsible for emotion and cognition.
Naunyn-Schmiedeberg s Archives of Pharmacology
February 1, 1977
R. K. Datta, J. J. Ghosh
2 citations
Slices of brain cortex remove methyl groups from mescaline, but at about one third the rate of a reference compound. The enzyme responsible, a demethylase, is found mostly in the soluble part of the cell and was purified 47-fold. It works best at pH 7.2 to 8.0, is stable for a few days with certain protective chemicals, and is inhibited by p-chloromercuribenzoate. The enzyme converts mescaline into two identified compounds—3,4-dimethoxy-5-hydroxyphenethylamine and 3,5-dimethoxy-4-hydroxyphenethylamine—plus some unidentified derivatives.